A Retrospective Analysis of Safety and Efficacy of Everolimus in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients That Showed Progression after PRRT Abstract #712

Introduction: GEP-NET patients have been treated successfully with SSAs. Upon progression, peptide receptor radiotherapy (PRRT) with 177Lu-octreotate is successful. PRRT is not unlimited. Some patients became refractory after therapy. There is a high medical need. Everolimus (mTOR inhibitor) is a promising therapy for progressive G1/G2 GEP-NETs, with well-established safety. Everolimus has shown efficacy in patients with (non-)PNET (RADIANT-2/-3). However, toxicity data of Everolimus after PRRT is lacking.
Aim(s): Investigate whether the safety profile of Everolimus is different after failure of PRRT.
Materials and methods: Seven men and six women (median age: 54.5 years) that received Everolimus (5 or 10 mg) at least once directly after PRRT failure were included. Baseline: last documented characteristics prior initiation Everolimus. Patients were assessed for safety parameters at baseline, including previously reported adverse events during PRRT and laboratory values. Progression-free survival (PFS) was analyzed using a KM curve.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: drs. Kimberly Kamp

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1297 Efficacy and Safety of Targeted Agents for Treatment of Gastroenteropancreatic (GEP) Neuroendocrine Tumor (NET): Single Center Experience
Introduction: As clinical features of NET are heterogeneous, the evaluation of real-world outcomes with everolimus and sunitinib are necessary.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Changhoon Yoo
Authors: Yoo C, Cho H, Kim K, Chang H M, ...
#1495 Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis
Introduction: Everolimus (EVE) demonstrated progression-free survival (PFS) benefit of 7.1 months compared to placebo in the phase 3 RADIANT-4 study in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Simron Singh
#892 Sunitinib in Gastroeneteropancreatic Neuroendocrine Tumor (GEP-NET) after Failure of Previous Treatments, Including Everolimus: A Series of Five Clinical Cases
Introduction: In a recent phase III study, Sunitinib has shown significant improvement of progression-free survival in patients with pancreatic NET.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Riccardo Marconcini
Keywords: sunitinib, everolimus
#186 Occurrence of Other Primary Malignancies in Patients with Endocrine Tumors of the Digestive Tract and Pancreas
Introduction: Endocrine tumors of the digestive tract and pancreas (GEP-NET) are often considered to be associated with other primary malignancies.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Kimberly Kamp
#467 Thoracic and Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) and Ectopic Adrenocorticotropin (ACTH) Syndrome (EAS)
Introduction: Ectopic Adrenocorticotropin (ACTH) Syndrome (EAS) is associated with a variety of malignancies, mostly of neuroendocrine origin. Several series report on the relative contribution of EAS in the spectrum of Cushing’s syndrome. However, information on the incidence/prevalence of EAS in the setting of patients diagnosed with thoracic or gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) is virtually absent.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Drs. Kimberly Kamp
Keywords: ACTH, GEP-NETS, Cushing
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.